Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

M. von Mehren; S. P. Balcerzak; A. S. Kraft; J. H. Edmonson; S. H. Okuno; M. Davey; S. Mclaughlin; M. T. Beard; A. Rogatko

doi:10.1155/2004/924913

Sarcoma (Jan 2004)

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas

M. von Mehren,
S. P. Balcerzak,
A. S. Kraft,
J. H. Edmonson,
S. H. Okuno,
M. Davey,
S. Mclaughlin,
M. T. Beard,
A. Rogatko

Affiliations

M. von Mehren: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
S. P. Balcerzak: Ohio State University, OH, USA
A. S. Kraft: University of Colorado, CO, USA
J. H. Edmonson: Mayo Clinic, Emory University, Atlanta, GA, USA
S. H. Okuno: Mayo Clinic, Emory University, Atlanta, GA, USA
M. Davey: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
S. Mclaughlin: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
M. T. Beard: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
A. Rogatko: Department of Biostatistics, Emory University, Atlanta, GA, USA

DOI: https://doi.org/10.1155/2004/924913
Journal volume & issue: Vol. 8, no. 4
pp. 107 – 111

Abstract

Read online

Patients:Soft tissue sarcomas are uncommon malignancies with few therapeutic options for recurrent or metastatic disease. Dolastatin-10 (Dol-10) is a pentapeptide anti-microtubule agent that binds to tubulin sites distinct from vinca alkaloids. Based on the novel mechanism of action, limited activity of other anti-microtubular agents, and anti-neoplastic activity in pre-clinical screening of Dol-10, this multi-institutional phase II study was conducted to determine the objective response rate of Dol-10 in recurrent or metastatic soft tissue sarcomas that had not been treated with chemotherapy outside of the adjuvant setting.

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal